Ratings Qol Holdings Co., Ltd.

Equities

3034

JP3266160005

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-10 am EDT			5-day change	1st Jan Change
1,850 ^JPY	+1.04%		+3.12%	+11.65%

Mar. 19	Qol to Secure 25 Billion Yen Bank Loan	MT
Mar. 18	Qol Holdings Co., Ltd. Announces Notice of Borrowing (Refinancing) of Funds	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company's attractive earnings multiples are brought to light by a P/E ratio at 13.02 for the current year.
The stock, which is currently worth 2024 to 0.42 times its sales, is clearly overvalued in comparison with peers.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company sustains low margins.

Ratings chart - Surperformance

Sector: Drug Retailers

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
QOL HOLDINGS CO., LTD.	+11.65%	443M		-
RAIA DROGASIL S.A.	-12.76%	8.54B		B
AIN HOLDINGS INC.	+33.93%	1.35B		-
NIHON CHOUZAI CO.,LTD.	+2.22%	274M		-
SALUS, LJUBLJANA, D. D.	+13.33%	232M	-	-
GREEN CROSS HEALTH LIMITED	-5.50%	88.89M	-	-
PETMED EXPRESS, INC.	-46.03%	83.22M		C
MEDICAL IKKOU GROUP CO.,LTD.	+19.24%	59.31M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes